Finnish Abomics and Swedish Gendoktorn Medicinsk Service ink distribution agreement over Pharmacogenetic Service

Finnish Abomics and Swedish Gendoktorn Medicinsk Service ink distribution agreement over Pharmacogenetic Service

Why Finland
Digital Health
Pharma
Diagnostics
Clinical Research
Research


In May 2018 Abomics, a Finnish health tech startup, launched the GeneAccount Service: a consumer test that allows a person to determine their medicine suitability in the most practical yet utmost trusted way. By a simple buccal swab, the response of approximately 20 genes to over 120 most common drugs are determined.

GeneAccount Service is based on a pharmacogenetic test which relies on high end professionals and advanced technology. In less than a month after the official launch, this unique service has received significant publicity and raised interest amongst press, consumers and the professionals.

Gendoktorn is a healthcare provider which has highly appreciated inhouse expertise and is considered as a forerunner within personalized medicine. Both companies value the collaboration highly and see the potential in utilizing pharmacogenetics information in daily clinical practice.

Entering a new market area, Sweden is strategically important for Abomics as it opens a new virgin market of pharmacogenetics. Gendoktorn is the first distributor in Sweden and both parties have high expectations regarding the co-operation and the business itself.

Further Information:

www.abomics.fi

www.geneaccount.com

CEO Jari Forsström, Abomics Ltd

+358 (0)40 544 1809, jari.forsstrom@abomics.fi

 

www.gendoktorn.se

CEO Lars Salmi, Gendoktorn Medicinsk Service i Göteborg AB

+46 (73) 2001003, lars.salmi@gendoktorn.se

 


Related posts